Our top pick for
IMV Inc is a biotechnology business based in the US. IMV shares (IMV) are listed on the NASDAQ and all prices are listed in US Dollars. IMV employs 62 staff and has a market cap (total outstanding shares value) of USD$225.5 million.
|52-week range||USD$1.35 - USD$6.31|
|50-day moving average||USD$3.763|
|200-day moving average||USD$3.7796|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.339|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-18,927,000|
|Return on assets TTM||-42.3%|
|Return on equity TTM||-106.34%|
|Market capitalisation||USD$225.5 million|
TTM: trailing 12 months
There are currently 585,452 IMV shares held short by investors – that's known as IMV's "short interest". This figure is 6% up from 552,524 last month.
There are a few different ways that this level of interest in shorting IMV shares can be evaluated.
IMV's "short interest ratio" (SIR) is the quantity of IMV shares currently shorted divided by the average quantity of IMV shares traded daily (recently around 319919.12568306). IMV's SIR currently stands at 1.83. In other words for every 100,000 IMV shares traded daily on the market, roughly 1830 shares are currently held short.
However IMV's short interest can also be evaluated against the total number of IMV shares, or, against the total number of tradable IMV shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IMV's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IMV shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable IMV shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IMV.
Find out more about how you can short IMV stock.
We're not expecting IMV to pay a dividend over the next 12 months.
IMV's shares were split on a 312:1000 basis on 10 May 2018. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 312 shares. This wouldn't directly have changed the overall worth of your IMV shares – just the quantity. However, indirectly, the new 220.5% higher share price could have impacted the market appetite for IMV shares which in turn could have impacted IMV's share price.
Over the last 12 months, IMV's shares have ranged in value from as little as $1.35 up to $6.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IMV's is 2.0599. This would suggest that IMV's shares are significantly more volatile than the average for this exchange and represent a higher risk.
IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.